JUN 0 9 2005

PTO/SB/08A (08-03)

Approved for use through 07/31/2006, OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number.

Substitute for last 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

	Complete If Known	
Application Number	10/518324	
Filing Date	December 15, 2004	
First Named Inventor	ERIC DEGUYON TAYLOR	
Group Art Unit	LINKNOWN- 1624	
Examiner Name	UNKNOWN K. Kabk	
Attorney Docket Number	BA9308USPCT	

			U.S. PATE	ENT DOCUMENTS		4
Examiner Initials *	Cite	ocument Number r Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	us-	10/518325				-Į³
KN	us-	2004/0209923	10-21-2004	BERGER ET AL.		4
- K K	us-	2004/0198984	10-07-2004	LAHM ET AL.		4
V II	US-	2004/0171649	09-02-2004	ANNIS ET AL.		4
VY	us-	2004/0198987	10-07-2004	FREUDENBERGER ET AL.		4
1 h	US-	2005/0075372	04-07-2005	LAHM ET AL.		4
	us-					4
	US-					4
	US-					⊣
	US -		L			\dashv
	US -				 	ㅓ
	US-					┨
	US-					ᅱ
	US.					-
	US-					ᅦ
	US -					ᅥ
	US				 	ᅥ
	US		 		 	\neg
	US		<u> </u>		 	_
	US	·				

		FOREIG	N PATENT D	OCUMENTS		
Examiner	Cite	Foreign Patent Document	Publication Date		Pages, Columns, Lines, Where Relevant Passages or Relevant	т.
Initials*	No.1	CountryCode ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Figures Appear	<u> </u>
VV	1	WO 03/ 015518 A1	02-27-2003	DUPONT		쁜
7	1 -	WO 03/ 015519 A1	02-27-2003	DUPONT		닏
	3	WO 03/ 016282 A2	02-27-2003	DUPONT		빝
	4	WO 03/ 016283 A1	02-27-2003	DUPONT	l	빝
}-	5	WO 01/70671 A2	09-27-2001	DUPONT		빝
	6	WO 04/011453	02-05-2004	DUPONT		ᄪ
 \ 	7	WO 03/024222	03-27-2003	DUPONT		
	+					
			 			

			. , ,
Examiner Signature	SHMM	Date Considered	3/6/2007

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.com/www.uspto.c

Influence of the process of the process of the properties of the properties of the properties of the process of the properties of the process of the process

X NOT A PATENT

PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE intend to respond to a collection of information unless it contains a valid CMB control number k Reduction Act of 1996, no persons are requ

Substitute for form Complete if Known **Application Number** 10/518324 INFORMATION DISCLOSURE December 15, 2004 Filing Date STATEMENT BY APPLICANT **ERIC DEGUYON TAYLOR** First Named Inventor Group Art Unit UNKNOWN Examiner Name UNKNOWN (use as many sheets as necessary) Attorney Docket Number BA9308USPCT

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS		
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
Kn	1	G.M. COPPOLA, THE CHEMISTRY OF 4H-3,1-BENZOXAZIN-4-ONES, J. HETEROCYCLIC CHEMISTRY, 1999, PAGES 563-588, VOL. 36		
Kn	2	JAKOBSEN ET. AL., INHIBITORS OF THE TISSUE FACTOR/FACTOR VIIA-INDUCED COAGULATION: SYNTHESIS AND IN VITRO EVALUATION OF NOVEL 2-ARYL SUBSTITUTED PYRIDO[3,4-D}-, PYRIDO [2,3-D][1,3]-, PYRAZINO[2,3-D][1,3}-, PYRIMIDO[4,5-D][1,3]-, PYRAZOLO[3,4-D}-, THIENO[3,2-D][1,3]-, AND THIENO[2,3-D][1,3]-OXAZIN-4-ONES, BIORGANIC AND MEDICINAL CHEMISTRY, 2000, PAGES 2803-2812, VOL. 8		
KN	3	JAKOBSEN ET. AL., INHIBITORS OF THE TISSUE FACTOR/FACTOR VIIA-INDUCED COAGULATION: SYNTHESIS AND IN VITRO EVALUATION OF NOVEL SPECIFIC 2-ARYL SUBSTITUTED 4H-3,1- BENZOXAZIN-4-ONES, BIORGANIC AND MEDICINAL CHEMISTRY, PAGES 2095-2103, VOL. 8		200
KN	4	D.V. RAMANA ET. AL., FACILE SYNTHESIS OF 2-ARYL-4H-3,1-BENZOXAZIN-4-ONES, ORG. PREP. PROCED. INT., 1993, PAGES 588-590, 1993, VOL. 25		
				·
1/2				
		·		
i				
Examiner		## Date 3 16/2007		<u>,</u>

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (08-03) Approved for use through 07/31/2006, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form ANDERPTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 10/518324

Filing Date December 15, 2004

First Named Inventor ERIC DEGUYON TAYLOR

Group Art Unit UNKNOWN

Examiner Name UNKNOWN

Attorney Docket Number BA9308USPCT

(use as many sheets as necessary)

Sheet 1 of 2

JUN 0 9 2005

U.S. PATENT DOCUMENTS Pages, Columns, Lines, Where **Document Number** Name of Patentee or **Publication Date** Examine Cite Applicant of Cited Document Relevant Passages or Relevant MM-DD-YYYY Number - Kind Code² (if known Initials * No. Figures Appear 10/518325 US -BERGER ET AL. 10-21-2004 2004/0209923 US -LAHM ET AL 10-07-2004 US -2004/0198984 ANNIS ET AL 09-02-2004 2004/0171649 US -FREUDENBERGER ET AL. 10-07-2004 US -2004/0198987 LAHM ET AL. 04-07-2005 2005/0075372 US -US us -US -บร us -US -US -US -US . บร -US us -US US -

		FOREIG	N PATENT D	OCUMENTS		
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	T ₆
Initials*	No.	CountryCode ³ Number ⁴ Kind Code ⁶ (# known)	MINFOUFITT		Figures Appear	
	41	WO 03/ 015518 A1	02-27-2003	DUPONT		片
	1 2	WO 03/ 015519 A1	02-27-2003	DUPONT		口
	3	WO 03/ 016282 A2	02-27-2003	· DUPONT		닏
- 1		WO 03/ 016283 A1	02-27-2003	DUPONT		Ш
		WO 01/70671 A2	09-27-2001	DUPONT		
	1 3	WO 04/011453	02-05-2004	DUPONT	-	
<u>'''</u>	6	WO 03/024222	03-27-2003	DUPONT		
<i>f</i>	7	VVO 03/024222	-			
		<u> </u>	 			\Box

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \(^1\) Applicant's unique citation designation number (optional). \(^2\) See Kinds Codes of CUSPTO Patent Documents at <a href="https://www.uspto.com/www.uspto.c

nanguage (ransiation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by This collection of information is required by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, the USPTO. Time will vary depending upon the individual case. Any including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any including gathering, preparing, and submitting the complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08B (08-03)

PTO/SB/08B (08-03)

Approved for use through 07/31/2005. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

at of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	Complete if Known
Application Number	10/518324
Filing Date	December 15, 2004
First Named Inventor	ERIC DEGUYON TAYLOR
Group Art Unit	UNKNOWN
Examiner Name	UNKNOWN
Attorney Docket Number	BA9308USPCT

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. 1		2	of 2 Attorney Docket Number BA930	8USPCT /	<u> </u>
Examiner Initials * Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. I G.M. COPPOLA, THE CHEMISTRY OF 4H-3,1-BENZOXAZIN-4-ONES, J. HETEROCYCLIC CHEMISTRY, 1999, PAGES 563-588, VOL. 36 JAKOBSEN ET. AL., INHIBITORS OF THE TISSUE FACTOR/FACTOR VIIIA-INDUCED COAGULATION: SYNTHESIS AND IN VITRO EVALUATION, OF NOVEL 2-ARYL SUBSTITUTED PYRIDO[3,4-D]-, PYRIDO (3,4-D]-, PYRIDO (3,			OTHER PRIOR ART - NON PATENT LITERATURE	DOCUMENTS	
G.M. COPPOLA, THE CHEMISTRY OF 4H-3,1-BENZOXAZIN-4-ONES, J. HETEROCYCLIC CHEMISTRY, 1999, PAGES 563-588, VOL. 36 JAKOBSEN ET. AL., INHIBITORS OF THE TISSUE FACTOR/FACTOR VIIA-INDUCED COAGULATION: SYNTHESIS AND IN VITRO EVALUATION, OF NOVEL 2-ARYL SUBSTITUTED PYRIDO(3,4-D)-, PYRIDO [2,3-D][1,3]-, PYRAZINO[2,3-D][1,3]-, PYRIMIDO(4,5-D][1,3]-, PYRAZOLO(3,4-D)-, THIENO(3,2-D][1,3]-, AND THIENO(2,3-D][1,3]-, OXAZIN-4-ONES, BIORGANIC AND MEDICINAL CHEMISTRY, 2000, PAGES 2803-2812, VOL. 8 JAKOBSEN ET. AL., INHIBITORS OF THE TISSUE FACTOR/FACTOR VIIA-INDUCED COAGULATION: SYNTHESIS AND IN VITRO EVALUATION OF NOVEL SPECIFIC 2-ARYL SUBSTITUTED 4H-3,1-BENZOXAZIN-4-ONES, BIORGANIC AND MEDICINAL CHEMISTRY, PAGES 2095-2103, VOL. 8 D.V. RAMANA ET. AL., FACILE SYNTHESIS OF 2-ARYL-4H-3,1-BENZOXAZIN-4-ONES, ORG. PREP. PROCED. INT., 1993, PAGES 588-590, 1993, VOL. 25			Include name of the author (in CAPITAL LETTERS), title of the	article (when appropriate), title of	T²
SYNTHESIS AND IN VITRO EVALUATION OF NOVEL 2-ARYL SUBSTITUTE P THIOLOGY, 2-Dj[1,3], AND [2,3-Dj[1,3], PYRAZOLOGY, 4-Dj, THIENOGY, 2-Dj[1,3], AND THIENOGY, 2-Dj[1,3], PYRAZOLOGY, 4-Dj, THIENOGY, 2-Dj[1,3], AND WEDICINAL CHEMISTRY, 2000, PAGES 2803-2812, VOL. 8 JAKOBSEN ET. AL., INHIBITORS OF THE TISSUE FACTOR/FACTOR VIIA-INDUCED COAGULATION: SYNTHESIS AND IN VITRO EVALUATION OF NOVEL SPECIFIC 2-ARYL SUBSTITUTED 4H-3,1-BENZOXAZIN-4-ONES, BIORGANIC AND MEDICINAL CHEMISTRY, PAGES 2095-2103, VOL. 8 D.V. RAMANA ET. AL., FACILE SYNTHESIS OF 2-ARYL-4H-3,1-BENZOXAZIN-4-ONES, ORG. PREP. PROCED. INT., 1993, PAGES 588-590, 1993, VOL. 25			G.M. COPPOLA, THE CHEMISTRY OF 4H-3, 1-BENZOXAZIN-4-ONES 1999, PAGES 563-588, VOL. 36	, J. HETEROCYCLIC CHEMISTRY,	
3 SYNTHESIS AND IN VITRO EVALUATION OF NOVEL SPECIFIC 2-ART L 3053THE SUBSTITUTE OF BENZOXAZIN-4-ONES, BIORGANIC AND MEDICINAL CHEMISTRY, PAGES 2095-2103, VOL. 8 D.V. RAMANA ET. AL., FACILE SYNTHESIS OF 2-ARYL-4H-3,1-BENZOXAZIN-4-ONES, ORG. PREP. PROCED. INT., 1993, PAGES 588-590, 1993, VOL. 25		2	SYNTHESIS AND IN VITRO EVALUATION, OF NOVEL 2-ARTL SUBS [3,2-D][1,3], PYRAZINO[2,3-D][1,3], PYRIMIDO[4,5-D][1,3], PYRAZOL THIENO[2,3-D][1,3], POXAZIN-4-ONES, BIORGANIC AND MEDICINAL CI	OI3 A-DL THIENOI3 2-DII1.31- AND	
PROCED. INT., 1993, PAGES 588-590, 1993, VOL. 25		3			
Division		4	D.V. RAMANA ET. AL., FACILE SYNTHESIS OF 2-ARYL-4H-3,1-BE PROCED. INT., 1993, PAGES 588-590, 199	NZOXAZIN-4-ONES, ORG. PREP. 13, VOL. 25	
Diffical					
		 	05(0)		
/ DUV				·	
		/	Dak		
	<u> </u>				
		+			
		+-			
Examiner Date	<u> </u>				

Signature *EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Applicant's unique ciauon designation number (optional). Applicant is to place a check mark here if english language i translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, useful of the properties, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any including gethering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.